STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 66 filers reported holding STEMLINE THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $5,955,000 | +16.7% | 556,567 | +18.2% | 0.00% | 0.0% |
| Q3 2016 | $5,102,000 | +72.1% | 471,055 | +7.5% | 0.00% | 0.0% |
| Q2 2016 | $2,965,000 | +56.6% | 438,016 | +7.8% | 0.00% | – |
| Q1 2016 | $1,893,000 | -25.9% | 406,268 | +0.4% | 0.00% | -100.0% |
| Q4 2015 | $2,553,000 | -26.2% | 404,544 | +3.2% | 0.00% | 0.0% |
| Q3 2015 | $3,460,000 | -25.9% | 391,825 | -1.2% | 0.00% | 0.0% |
| Q2 2015 | $4,667,000 | -21.8% | 396,517 | -3.8% | 0.00% | 0.0% |
| Q1 2015 | $5,965,000 | +6.2% | 412,243 | +25.2% | 0.00% | 0.0% |
| Q4 2014 | $5,617,000 | +64.7% | 329,254 | +20.3% | 0.00% | 0.0% |
| Q3 2014 | $3,410,000 | -18.5% | 273,698 | -4.0% | 0.00% | 0.0% |
| Q2 2014 | $4,183,000 | -24.4% | 285,109 | +4.9% | 0.00% | -50.0% |
| Q1 2014 | $5,532,000 | +7.4% | 271,721 | +3.4% | 0.00% | 0.0% |
| Q4 2013 | $5,149,000 | -56.2% | 262,713 | +1.2% | 0.00% | -50.0% |
| Q3 2013 | $11,760,000 | +115.3% | 259,622 | +13.3% | 0.00% | +100.0% |
| Q2 2013 | $5,462,000 | – | 229,093 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lyon Street Capital, LLC | 762,941 | $7,248,000 | 7.29% |
| NEXTHERA CAPITAL LP | 711,558 | $6,760,000 | 2.79% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 585,930 | $4,366,000 | 2.71% |
| Consonance Capital Management LP | 1,155,793 | $10,980,000 | 0.81% |
| Pier Capital, LLC | 423,667 | $4,025,000 | 0.80% |
| KNOTT DAVID M | 155,795 | $1,480,000 | 0.70% |
| Eventide Asset Management | 1,086,400 | $10,321,000 | 0.46% |
| Empire Life Investments Inc. | 373,863 | $3,552,000 | 0.32% |
| Telemetry Investments, L.L.C. | 41,588 | $395,000 | 0.25% |
| Polar Capital LLP | 2,302,666 | $21,875,000 | 0.23% |